9 results about "Meningioma" patented technology

The application discloses a double-branch Raio gating graph aggregation multi-modal meningioma segmentation method, belongs to the cross technical field of computer vision and medical image processing, is used for meningioma segmentation, and comprises the following steps: preparing a data set, constructing a deep neural network model, and performing neural network training; inputting the data set into the trained deep neural network model; first inputting a double-branch multi-modal input module to output a multi-modal fusion feature tensor; then inputting the multi-modal fusion feature tensor into a hierarchical Swin Transformer encoder to output three-dimensional segmentation masks of enhanced tumors, tumor cores and whole tumor regions of meningioma. Through double-branch multi-modal input fusion, hierarchical Swin Transformer coding, edge perception modulation and Laplace gating graph aggregation, high-precision three-dimensional segmentation of enhanced tumors, tumor cores and whole tumor regions of meningioma is realized.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.

The invention provides a method and a system for predicting the growth risk of accidental asymptomatic meningioma. The method comprises the following steps: acquiring baseline clinical data, iconomic semantic feature data and iconomic feature data of a patient suffering from accidental asymptomatic meningioma; dividing the patient queue into a training set, a verification set and a test set, screening independent prediction factors significantly related to tumor growth, training a random survival forest model based on the training set, and performing optimization and verification in the verification set and the test set to generate an optimal model for predicting the individualized time-dependent growth risk; and inputting related data of a patient to be predicted into the optimal model, and outputting meningioma growth risk assessment results at different time points in the future. According to the invention, the technical problem that a patient with primary asymptomatic meningioma lacks an individualized natural growth trend prediction tool is solved.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological conditions including grade IV glioblastoma, grade 3 glioma, embryonal tumor, pituitary tumor, meningioma, hemangiopericytoma, hemangioblastoma, mesothelioma, cholangiocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urinary tract cancer, bladder adenocarcinoma, and esophageal cancer, as well as for use in the treatment of peripheral diabetic neuropathy, spinal cord injury, postherpetic neuralgia, chemotherapeutic agents, antitumor agents, cancer, fibromyalgia, or neuropathic pain caused by hepatitis. The present invention also relates to pharmaceutical compositions comprising 2-hydroxy-octadecene-9-cis-oate.

The present application relates to a meningioma infiltration boundary resection strategy optimization method, which uses the stress and strain response difference during intraoperative tissue traction and suction operation to mark the biomechanical abnormal area in space; constructs a mechanical residual atlas; extracts the local tissue compliance critical point as the physiological landmark of the infiltration boundary; identifies the high adaptability channel in the three-dimensional tissue atlas; makes partition modeling for the structural impedance of different regions; constructs a boundary evolution stability hot area map, maps the boundary prediction result back to the current operation scene, and is used to judge whether the resection range needs to be expanded; after each tissue stripping or resection, the corresponding regional tissue deformation rate, blood supply flow rate and temperature diffusion mode indicators are collected as the reflection of the intraoperative boundary stress response, which is used to evaluate whether the high-risk area has been touched by the resection behavior; once the boundary stress index exceeds the preset threshold, the system freezes the path segment, calculates the alternative path, improves the accuracy of boundary identification, and reduces the damage to the functional area and the recurrence risk.

The application discloses application of RPL27A gene and / or RPL27A protein in preparation of a meningioma treatment drug. The application provides a new meningioma treatment target, and the RPL27A has a significant anti-meningioma function, can inhibit occurrence, development and metastasis of meningioma, and has wide clinical application value for development of a new meningioma diagnosis marker and a treatment drug.

The invention provides application of a compound in preparation of a medicine for inhibiting G3BPs, and belongs to the technical field of biological medicine. The medicine is used for treating tumors, neurodegenerative diseases or virus infection; the tumors comprise any one or a combination of lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, pancreatic cancer, cervical cancer, skin cancer, osteosarcoma, liposarcoma, smooth muscle sarcoma, leukemia, lymphoma, multiple myeloma, glioma, meningioma, testicular cancer, endometrial cancer, cervical cancer, ovarian cancer, melanoma, thyroid cancer, kidney cancer or bladder cancer. When the compound shown in the formula (I) is combined with different anti-tumor drugs in various tumor cells, the sensitivity of the cells to the anti-tumor drugs can be improved, so that the drug resistance of the tumor cells is reduced.